Results 41 to 50 of about 2,519,772 (150)

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury

Cells, 2021
Recent studies on liver disease burden worldwide estimated that cirrhosis is the 11th most common cause of death globally, and there is a great need for new therapies to limit the progression of liver injuries in the early stages.
Anca D. Petrescu, Sharon DeMorrow
doaj   +1 more source

New treatments/targets for primary biliary cholangitis

JHEP Reports, 2019
Summary: Primary biliary cholangitis (PBC) is an autoimmune, cholestatic, chronic liver disease that ultimately progresses towards cirrhosis and liver failure if untreated.
Christophe Corpechot, Raoul Poupon, Olivier Chazouillères   +2 more
doaj   +1 more source

Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway

Frontiers in Immunology, 2022
Hepatocellular carcinoma (HCC) is the most common type of liver malignancy with a high incidence and mortality rate. Previous in vitro and in vivo studies have confirmed that liver sinusoidal endothelial cells (LSEC) secrete CXCL16, which acts as a ...
Haoxian Gou, Haoxian Gou, Shenglu Liu, Linxin Liu, Ming Luo, Shu Qin, Kai He, Kai He, Xiaoli Yang, Xiaoli Yang   +9 more
doaj   +1 more source

OBETICHOLIC ACID: AN INSIGHT INTO A QUANTITATIVE DETERMINATION AND METHODOLOGICAL VALIDATION THROUGH NUCLEAR MAGNETIC RESONANCE [PDF]

, 2020
Objective: The research work unveils the use of nuclear magnetic resonance (NMR) technique for quantitative determination and method validation of obeticholic acid.
KUMAR, AJAY, SAHU, RAKESH, MAZUMDER, RUPA, MAJEE, CHANDANA, MISHRA, RAKHI   +4 more
core   +1 more source

Evolving Role for Pharmacotherapy in NAFLD/NASH

Clinical and Translational Science, 2021
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma.
Suzanna L. Attia, Samir Softic, Marialena Mouzaki   +2 more
doaj   +1 more source

Effects of post‐hepatic portoenterostomy adjuvant therapy on liver transplantation in children with biliary atresia: A systematic review

JPGN Reports, EarlyView.
Abstract Objectives Biliary atresia (BA) is a cholangiopathy characterized by obstruction of the intrahepatic and extrahepatic bile ducts. Hepatic portoenterostomy (HPE) is the primary palliative treatment and there is still an urgent need to improve post‐HPE management.
Bianca Ferraz de Almeida Silva, Alice Palmeira Nascimento Cerqueira, Breno Oliveira Marques, Gabriela Garcia de Carvalho Laguna, Gabrielle dos Santos Aguiar, Luana Leal Gonzaga, Raquel Teles de Lacerda, Natalia Oliveira e Silva   +7 more
wiley   +1 more source

Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters

Journal of Lipid Research, 2017
The farnesoid X receptor (FXR) plays critical roles in plasma cholesterol metabolism, in particular HDL-cholesterol (HDL-C) homeostasis. Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. Previous studies
Bin Dong, Mark Young, Xueqing Liu, Amar Bahadur Singh, Jingwen Liu   +4 more
doaj   +1 more source

Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow‐Up

Hepatology Research, EarlyView.
Impairment of health‐related quality of life in patients with PBC, in particular observed in younger female, represents distinct dimensions of disease impact, independently of long‐term outcomes. Overall and interindividual changes in PBC‐40 scores greatly varied over 10 years, suggesting that symptom burdens are driven by heterogeneous underlying ...
Akihito Takeuchi, Atsumasa Komori, Kazuhito Kawata, Osamu Yoshida, Kazunari Tanaka, Kazumichi Abe, Yukihisa Fujinaga, Tadashi Namisaki, Naruhiro Kimura, Tomohiro Katsumi, Ryo Miura, Naoko Tachizawa, Yoshinari Asaoka, Yoshiyuki Ueno, Shuji Terai, Hiromasa Ohira, Hitoshi Yoshiji, Kentaro Kikuchi, Takeshi Matsui, Tadashi Ikegami, Akira Honda, Masanori Abe, Atsushi Tanaka   +22 more
wiley   +1 more source

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease

Drug Design, Development and Therapy, 2019
Dan-Ying Zhang,1,* Lin Zhu,2,* Hai-Ning Liu,1,* Yu-Jen Tseng,3 Shu-Qiang Weng,1 Tao-Tao Liu,1 Ling Dong,1 Xi-Zhong Shen1,41Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, People’s Republic of China ...
Zhang DY, Zhu L, Liu HN, Tseng YJ, Weng SQ, Liu TT, Dong L, Shen XZ   +7 more
doaj  

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis

Journal of Experimental Pharmacology, 2020
Annarosa Floreani1,2 1University of Padova, Padova, Italy; 2Scientific Institute for Research, Hospitalization and Healthcare, Negrar, Verona, ItalyCorrespondence: Annarosa FloreaniUniversity of Padova, Padova, ItalyTel +10393899418841Email annarosa ...
Floreani A
doaj